Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or Enzalutamide

NCT02379390 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

8

Enrollment

INDUSTRY

Sponsor class

Stopped Unsatisfactory patient accrual

Conditions

Prostate Cancer Metastatic

Interventions

DRUG: Cabazitaxel XRP6258
DRUG: Ezalutamide
DRUG: Abiraterone acetate
DRUG: Prednisone

Sponsor

Sanofi